In vivo adenoviral transfer of sorcin reverses cardiac contractile abnormalities of diabetic cardiomyopathy

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 286, Issue 1 55-1, 2004, Pages

  Suarez, Jorge ^a   Belke, Darrell D ^a   Gloss, Bernd ^a   Dieterle, Thomas ^a   McDonough, Patrick M ^a   Kim, Yun Kyung ^a   Brunton, Laurence L ^b   Dillmann, Wolfgang H ^a,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b San Diego   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Calcium handling; Gene therapy

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOVIRUS VECTOR; CALCIUM ION; RYANODINE RECEPTOR; SORCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM TRANSPORT; CARDIOMYOPATHY; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DOWN REGULATION; DRUG MECHANISM; DRUG PROTEIN BINDING; GENE OVEREXPRESSION; GENE THERAPY; GENE TRANSFER; HEART CONTRACTION; HEART MUSCLE CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM;

EID: 0347628951     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00245.2003     Document Type: Article

References (28)

1. Ahmed SS, Jaferi GA, Narang RM, and Regan TJ. Preclinical abnormality of left ventricular function in diabetes mellitus. Am Heart J 89: 153-158, 1975.
2. Bers DM. Excitation-Contraction Coupling and Cardiac Contractile Force. Dordrecht, The Netherlands: Kluwer Academic, 2001.
3. Farrell EF, Antaramian A, Rueda A, Gomez AM, and Valdivia HH. Sorcin inhibits calcium release and modulates excitation-contraction coupling in the heart. J Biol Chem 278: 34660-34666, 2003.
4. Ganguly PK, Pierce GN, Dhalla KS, and Dhalla NS. Defective sarcoplasmic reticular calcium transport in diabetic cardiomyopathy. Am J Physiol Endocrinol Metab 244: E528-E535, 1983.
5. 2+ transients. Circulation 96: 400-403, 1997.
6. Gracy KN, Clarke CL, Meyers MB, and Pickel VM. N-methyl-D-aspartate receptor 1 in the caudate-putamen nucleus: ultrastructural localization and co-expression with sorcin, a 22,000 mol. wt calcium binding protein. Neuroscience 90: 107-117, 1999.
7. 2+-ATPase activity and cardiac myocyte contractility. Circulation 100: 974-980, 1999.
8. Lew WY, Lee M, Yasuda S, and Bayna E. Depyrogenation of digestive enzymes reduces lipopolysaccharide tolerance in isolated cardiac myocytes. J Mol Cell Cardiol 29: 1985-1990, 1997.
9. Lokuta AJ, Meyers MB, Sander PR, Fishman GI, and Valdivia HH. Modulation of cardiac ryanodine receptors by sorcin. J Biol Chem 272: 25333-25338, 1997.
10. Mahler F, Ross J Jr, O'Rourke RA, and Covell JW. Effects of changes in preload, afterload and inotropic state on ejection and isovolumic phase measures of contractility in the conscious dog. Am J Cardiol 35: 626-634, 1975.
11. 2+-binding proteins with five EF-hand motifs. Biochem J 328: 718-720, 1997.
12. Meyers MB. Novel Calcium-Binding Proteins: Fundamentals and Clinical Implications. Berlin: Springer, 1991.
13. Meyers MB, Fischer A, Sun YJ, Lopes CM, Rohacs T, Nakamura TY, Zhou YY, Lee PC, Altschuld RA, McCune SA, Coetzee WA, and Fishman GI. Sorcin regulates excitation-contraction coupling in the heart. J Biol Chem 278: 28865-28871, 2003.
14. Meyers MB, Pickel VM, Sheu SS, Sharma VK, Scotto KW, and Fishman GI. Association of sorcin with the cardiac ryanodine receptor. J Biol Chem 270: 26411-26418, 1995.
15. 2+ channels. J Biol Chem 273: 18930-18935, 1998.
16. Meyers MB, Zamparelli C, Verzili D, Dicker AP, Blanck TJ, and Chiancone E. Calcium-dependent translocation of sorcin to membranes: functional relevance in contractile tissue. FEBS Lett 357: 230-234, 1995.
17. Okamoto Y, Chaves A, Chen J, Kelley R, Jones K, Weed HG, Gardner KL, Gangi L, Yamaguchi M, Klomkleaw W, Nakayama T, Hamlin RL, Carnes C, Altschuld R, Bauer J, and Hai T. Transgenic mice with cardiac-specific expression of activating transcription factor 3, a stress-inducible gene, have conduction abnormalities and contractile dysfunction. Am J Pathol 159: 639-650, 2001.
18. 2+ leak from the sarcoplasmic reticulum and increases contractility. Circ Res 88: 188-194, 2001.
19. Rubler S, Sajadi RM, Araoye MA, and Holford FD. Noninvasive estimation of myocardial performance in patients with diabetes. Effect of alcohol administration. Diabetes 27: 127-134, 1978.
20. Sahn DJ, DeMaria A, Kisslo J, and Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58: 1072-1083, 1978.
21. 2+ leak-load relationship. Circ Res 91: 594-600, 2002.
22. Tanaka N, Dalton N, Mao L, Rockman HA, Peterson KL, Gottshall KR, Hunter JJ, Chien KR, and Ross J Jr. Transthoracic echocardiography in models of cardiac disease in the mouse. Circulation 94: 1109-1117, 1996.
23. 2+ channel mRNA in streptozotocin-induced diabetic rat heart. J Mol Cell Cardiol 32: 655-664, 2000.
24. 2+-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes 51: 1166-1171, 2002.
25. Trost SU, Omens JH, Karlon WJ, Meyer M, Mestril R, Covell JW, and Dillmann WH. Protection against myocardial dysfunction after a brief ischemic period in transgenic mice expressing inducible heat shock protein 70. J Clin Invest 101: 855-862, 1998.
26. 2+ levels in the heart by sorcin and FKBP12, two accessory proteins of ryanodine receptors. Trends Pharmacol Sci 19: 479-482, 1998.
27. 2+ leak through ryanodine receptor in heart failure. Circulation 102: 2131-2136, 2000.
28. Zamparelli C, Ilari A, Verzili D, Vecchini P, and Chiancone E. Calcium- and pH-linked oligomerization of sorcin causing translocation from cytosol to membranes. FEBS Lett 409: 1-6, 1997.